Addressing Obesity to Prevent Diabetes: Insights from STEP and SURMOUNT Trials
Overview
Obesity is the primary risk factor for prediabetes, which significantly increases the risk of type 2 diabetes and cardiovascular disease. Pharmacological agents targeting the incretin axis, including GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, have demonstrated substantial efficacy in promoting weight loss and preventing progression to diabetes in individuals with obesity and prediabetes.
Background
Prediabetes is a prevalent condition characterized by impaired glucose regulation and is strongly linked to obesity. Lifestyle interventions remain the cornerstone of diabetes prevention but often yield limited long-term success. Advances in pharmacotherapy, particularly agents modulating the incretin effect such as GLP-1 receptor agonists (liraglutide, semaglutide) and dual GLP-1/GIP receptor agonists (tirzepatide), have emerged as effective strategies to reduce weight and improve glycemic control. These therapies address both the pathophysiological defects in insulin secretion and the excess adiposity that drive diabetes onset.
Data Highlights
Agent
Trial
Weight Loss (%)
Diabetes Risk Reduction
Duration
Liraglutide
SCALE Obesity Prediabetes
6.1%
79% reduction in diabetes incidence
3 years
Semaglutide
STEP 1,3,4,10; SELECT
~15.4%
Significant reversion to normoglycemia and reduced progression
Varied (up to 3 years)
Tirzepatide
SURMOUNT-1; Phase 3 diabetes prevention trial
20.9%
Unprecedented reduction in diabetes onset
Varied
Key Findings
Obesity is the leading modifiable risk factor for prediabetes and subsequent type 2 diabetes.
Liraglutide reduced diabetes incidence by 79% over 3 years in overweight/obese patients with prediabetes (SCALE trial), with 66% regressing to normoglycemia.
Semaglutide demonstrated consistent weight loss (~15.4%) and improved glycemic outcomes across multiple STEP trials and the SELECT cardiovascular outcomes trial.
Tirzepatide achieved the greatest weight loss (~20.9%) and showed superior diabetes prevention efficacy compared to semaglutide in recent real-world data.
The incretin effect, mediated by GLP-1 and GIP, is impaired in type 2 diabetes and obesity, providing a mechanistic rationale for incretin-based therapies.
Pharmacotherapy targeting the incretin axis complements lifestyle interventions by improving beta-cell function, insulin sensitivity, and reducing oxidative stress.
Clinical Implications
Incorporating GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists into treatment regimens for patients with obesity and prediabetes can substantially reduce progression to type 2 diabetes. These agents offer durable weight loss and improved glycemic control beyond lifestyle modification alone. Clinicians should consider these pharmacotherapies as part of a comprehensive diabetes prevention strategy, especially in high-risk individuals.
Conclusion
Antiobesity pharmacotherapy targeting the incretin axis represents a pivotal advancement in preventing type 2 diabetes among patients with obesity and prediabetes. The robust evidence from the STEP and SURMOUNT trials underscores the potential to modify disease trajectory and achieve meaningful clinical outcomes.
References
De Fronzo RA 2009 -- The Ominous Octet in Type 2 Diabetes Pathogenesis
SCALE Obesity Prediabetes Trial -- Liraglutide for Diabetes Prevention
STEP and SELECT Trials -- Semaglutide in Obesity and Diabetes Prevention
SURMOUNT-1 Trial -- Tirzepatide for Obesity and Diabetes Prevention
